Inhibitors of histone deacetylase

Patent metadata

Field	Value
Publication number	US-9988343-B2
Application number	US-201415034276-A
Country	US
Kind code	B2
Filing date	Nov 5, 2014
Priority date	Nov 5, 2013
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

First claim

The invention claimed is:

1. A compound of formula Ia1, Ia2, Ia3, Ia4, Ia5, Ia6, Ib, or Ic:

wherein:
Ar is unsubstituted or substituted phenyl, unsubstituted or substituted pyrazinyl, unsubstituted or substituted pyrimidinyl, unsubstituted or substituted pyridinyl, unsubstituted or substituted quinolinyl, unsubstituted or substituted isoquinolinyl, unsubstituted or substituted quinazolinyl, or unsubstituted or substituted quinoxalinyl;
R 1 and R 2 are each independently H, hydroxyl, cyano, halogen, unsubstituted or substituted amino, unsubstituted or substituted C 1 -C 6 alkyl, or unsubstituted or substituted C 1 -C 6 alkoxy;
each R is independently hydroxyl, cyano, halogen, unsubstituted or substituted amino, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 alkoxy, or unsubstituted or substituted C 6 -C 10 aryl;
Y′ is hydroxyl, cyano, halogen, unsubstituted or substituted amino, unsubstituted or substituted C 1 -C 6 alkyl, or unsubstituted or substituted C 1 -C 6 alkoxy;
Y is halogen;
x is 0, 1, 2, or 3;
x′ is 0, 1, 2, or 3;
y is 0, 1, 2, 3, or 4;
z is 0, 1, or 2:
R 3 is H, unsubstituted C 1 -C 6 alkyl, halogen, or NT n1 T n2 ;
T n1 and T n2 are each independently H, unsubstituted C 1 -C 6 alkyl, or C(O)X 1 ;
R 4 is H, unsubstituted or substituted C 1 -C 6 alkyl, halogen, or NT n3 T n4 ;
T n3 and T n4 are each independently H, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 6 -C 10 aryl, or C(O)X 1 ; and
X 1 is unsubstituted or substituted C 1 -C 6 alkyl,
provided that when Ar is unsubstituted pyrazinyl, x is not 0,
provided that when R 4 is H and x′ is 0, x is not 0, and
provided the compound is not 4-(acetylamino)-N-(2-aminophenyl)benzamide or pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate,

or a pharmaceutically acceptable salt or ester thereof.

2. The compound of claim 1 , wherein
the compound is a compound of formula Ia1, and R 3 is unsubstituted C 1 -C 6 alkyl, halogen, or NT n1 T n2 ; or
the compound is a compound of formula Ib or Ic, and Ar is substituted phenyl.

3. The compound of claim 1 , wherein
the compound is a compound of formula Ia4, Ia5, or Ia6; or
the compound is a compound of formula Ib or Ic, and Ar is unsubstituted or substituted pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl.

4. The compound of claim 1 , wherein
the compound is a compound of formula Ia2; or
the compound is a compound of formula Ib or Ic, and Ar is unsubstituted or substituted pyrimidin-5-yl.

5. The compound of claim 1 , wherein
the compound is a compound of formula Ia3; or
the compound is a compound of formula Ib or Ic, and Ar is unsubstituted or substituted pyrazinyl.

6. The compound of claim 1 , wherein
the compound is a compound of formula Ia1, Ia2, Ia4, Ia5, Ia6, or Ib, and R 1 is H; or
the compound is a compound of formula Ic, and R 2 is hydroxyl or unsubstituted or substituted amino.

7. The compound of claim 1 , wherein
the compound is a compound of formula Ia1, Ia2, Ia4, Ia5, Ia6, or Ib, and R 1 is halogen; or
the compound is a compound of formula Ic, and R 2 is hydroxyl or unsubstituted or substituted amino.

8. The compound of claim 1 , wherein
the compound is a compound of formula Ic, R 2 is H; or
the compound is a compound of formula Ia1, Ia2, Ia4, Ia5, Ia6, or Ib, and R 1 is halogen.

9. The compound of claim 1 , wherein x is 1, 2, or 3.

10. The compound of claim 1 , wherein:
the compound is a compound of formula Ib or Ic; and
Ar is unsubstituted or substituted phenyl, unsubstituted or substituted pyrazinyl, unsubstituted or substituted pyrimidinyl, or unsubstituted or substituted pyridinyl.

11. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier.

12. A method of treating a hematological cell proliferative disorder in a subject, comprising administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier.

13. The method of claim 12 , wherein the hematological cell proliferative disorder is a multiple myeloma.

14. The method of claim 13 , further comprising administering to the subject a second therapeutic agent.

15. The method of claim 14 , wherein the second therapeutic agent is selected from the group consisting of an HDAC inhibitor, a proteasomal inhibitor, a deubiquitinase inhibitor, a demethylase inhibitor, an endoplasmic reticulum (ER) stressor, a JNK inhibitor, and a caspase inhibitor.

16. The method of claim 15 , wherein the second therapeutic agent is a proteasomal inhibitor.

17. The method of claim 16 , wherein the proteasomal inhibitor is bortezomib.

18. The compound of claim 1 , wherein the compound is a compound of formula Ia1, Ia2, Ia3, Ia4, Ia5, Ia6, Ib, or Ic, or a pharmaceutically acceptable salt or solvate thereof.

19. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. A method of treating a hematological cell proliferative disorder in a subject, comprising administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. A compound selected from the group consisting of

or a pharmaceutically acceptable salt or ester, solvate, or prodrug thereof.

22. The compound of claim 21 , wherein the compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

Assignees

• Dana Farber Cancer Inst Inc
• Massachusetts Gen Hospital

Inventors

• Mazitschek Ralph
• Hideshima Teru
• Anderson Kenneth C
• Haggarty Stephen J
• Ghosh Balaram

Classifications

• C07C237/40 Primary

  having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring · CPC title

• C07D239/42

  One nitrogen atom (nitro radicals C07D239/30) · CPC title

• C07D213/82

  in position 3 · CPC title

• A61K31/167 Primary

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

• A61K31/4406

  only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455) · CPC title